Dômes Pharma Foundation presents the projects supported in 2020-2021

To illustrate its slogan Linked by Nature with concrete actions and pay tribute to the passion and values of its founders, the Dômes Pharma Group has created a Corporate Foundation for animal mediation in 2019. Its mission is to support projects that allow the most vulnerable people (sick, disabled, elderly) to share a moment of complicity, relaxation or care with an animal in order to benefit from the profound and lasting benefits of this relationship. For its 2022 greetings card, the Group has chosen the Association Soleil AFELT and the animal mediation sessions it offers to children hospitalised in the paediatric oncology and neuropaedics departments of the CHU in Angers.

In 2011, the Soleil AFELT Charity for families of children suffering from leukaemia or tumours offered animal mediation sessions to children hospitalised at the Dijon University Hospital for the first time. The benefits having been unanimously acclaimed, since 2019, an identical programme has been offered to children hospitalised in the paediatric oncology and neuro-paediatric units of the CHU in Angers. The objective for the Soleil AFELT charity is to improve the daily life of the child during his or her hospitalisation, to facilitate his or her adaptation to the care process and to accompany the family during a time of shared well-being. The animal is a mediator that provides emotional support to the child, facilitates observation and appeasement, allows the expression of emotions and acts as a diversion to anxiety:

“When he was able to be in contact with the animals, our son was like hypnotised. He would smile again. He took a lot of pleasure in petting and caring for them. You could see in his eyes that this moment was a real time of pleasure and appeasement. For a moment, the pain was in the background and he could finally enjoy a few minutes of well-being.”
Testimony of the mother of one of the beneficiaries of the animal mediation sessions offered by Soleil AFELT

Soleil AFELT is one of the 22 charities that have benefited from the financial support of the Foundation. Some of the projects supported in 2020-2021:

Founded in 2008, the association “Gamelles Pleines” is a national federation of regional and departmental associations under the 1901 law, present in 11 cities in France. Gamelles Pleines fights against the social exclusion of people in precarious situations by acting through the animal dimension because the pet, and in particular the dog, sometimes remains their only social link, their only friend, and sometimes even their only reason to survive. Wanimo’s employees regularly participate in the association’s marauding in Lyon and have already carried out 2 operations to distribute kits for animals in the street: blankets and folding bowls. Each year, the calendar of the association is sold on the site of Wanimo.

The project: The Dômes Pharma Foundation has granted a subsidy to enable Gamelles Pleine to provide emergency assistance for the care of homeless animals, particularly in Toulouse in the context of the parvovirus epidemic.

The veterinarians in the sports sector of the Unit of Animal Husbandry and Sports Medicine (UMES) deal with sports dogs (such as agility dogs) and utility dogs (such as drug search dogs). The medicine of sport and utility dogs has three aspects: the preventive aspect, the diagnostic aspect and the aspect of optimising physical performance.

The project: NOSAÏS COVID: Training dogs to detect COVID 19

In March 2020, the UMES of Maisons Alfort, under the responsibility of Professor Dominique Grandjean, Professor at the Veterinary School of Maisons Alfort and Colonel of the Paris Fire Brigade, launched a study called NOSAÏS to verify the capacity of dogs already working with firefighters to identify patients with COVID 19 by smell. The tests carried out proved to be very positive, as 95% of the dogs tested identified the correct samples. These dogs required 4-5 days of training. Several trials have been launched in several regions of France, including Corsica, and in several countries including Belgium, Germany, Lebanon, Canada, Norway, the United Kingdom and the United Arab Emirates, with equally satisfactory results.

Since 2010, LES CHIENS DU SILENCE is an association that trains and gives free listening guide dogs to deaf or hard of hearing people. Hearing dogs alert deaf or hard of hearing people to the sounds of their daily lives and give them independence and confidence. The arrival of a hearing assistance dog changes the lives of these people: its mission is to replace their ears and reassure them in their daily lives!

At the end of their long training, all hearing assistance dogs are able to help at home to wake up in the morning, to indicate that the telephone is ringing, to show that a child is calling “mummy” or “daddy” or crying, to show the ringing of a door or an intercom, or outside to feel safe when using a bicycle, motorbike or scooter, a motorbike or scooter is coming from behind, to mark the arrival of a car, tram or metro, in a car to indicate the fire, police or ambulance siren or in general, all noises that can indicate danger!

The project: The Association approached the Foundation with the aim of obtaining a financial grant for the expansion of a kennel for its dogs. Biocanina joined the Foundation to support the association and to pay for part of the internal and external antiparasitics for the dogs in training.

The LA RONZIERE association houses 80 animals (horses, farm animals and pets) and welcomes, for animal mediation sessions, people from the Educational Medical Institutes, the Children’s Centre, the Emergency Adolescent Psychiatry Service of the Clermont CHU, but also residents of the EHPAD. A scientific committee participates in each session to observe and analyse practices. The association has to deal with the upkeep (food, care, etc.) of its animals, even though the mediation sessions have been partly interrupted due to the health crisis, and wishes to buy a disabled saddle and a safety ramp.

Project supported: The association has applied for a grant for operating costs.

Created in September 2019, the SOLIVET association supports the integration of people in very precarious situations, with their pets. In France, the Fondation Abbé Pierre estimates that nearly 902,000 people are without personal housing, including about 260,000 homeless people. Of these, up to a third may own a pet, i.e. approximately 100,000 homeless pet owners. SoliVet’s aim is to ensure that animals are no longer an obstacle to social inclusion and to staying in accommodation and housing, as animals are a strong social vector and an asset for housing.

Project supported: Initiate a 3-year programme to support 3 social structures that manage shelters for the homeless, with the aim of better integrating animals into their social work, by training the staff of these structures, proposing animal mediation activities and veterinary follow-up.

The mission of the Fondation Frédéric GAILLANNE is to provide young minors with sensory, motor or mental disabilities with guide dogs and other technical aids in order to give them access to all dimensions of the human experience and to enable them to develop their autonomy.

Project supported: The Dômes Pharma Foundation has awarded a grant to conduct a study on the impact of the daily provision of a dog to blind babies (from 15 months of age) by asking volunteer families to film targeted footage every month for two years, which will then be analysed in the long term by professionals. This project is a collaboration between the University of Lyon II, the CTRDV of Lyon and the PEP 69, the Mira Canada Foundation and the Fondation Frédéric Gaillanne.

The association AVA (Agir pour la Vie Animale) saves and protects old animals by opposing arbitrary slaughter and by taking care of each of them until the end of their lives. To this end, the animals are given a unique place to live dedicated to their well-being and a “retirement home” for elderly dogs. In 30 years, AVA has saved the lives of thousands of animals who were condemned because of their age, disability, illness, “troublesome” behaviour or simply because they had become “unprofitable”, “undesirable”. In 2019, the association tested a new pet therapy project that brings together patients suffering from post-traumatic stress (in partnership with the Victimology Institute) and the animals themselves, often victims of trauma and having escaped euthanasia.

The project supported: to perpetuate the pet therapy project for a second year. Based on the complicity between Man and Animal, this programme, tested in 2019, takes place at the Refuge over several months. It is subject to evaluation and scientific monitoring on both the human and animal levels. It has proven to be effective in recreating a social link both for these traumatised people and for the carefully selected animals that accompany them. This programme is aimed at both people and animals who have been badly affected by life. Beyond the differences between the two species, each living being finds comfort in the other. Each is there to give the other a little of what they lack, without judgement.

The association was created at the beginning of 2021 by two veterinarians who have been treating pets for more than 15 years. From their practice, they have learned that when an animal is ill and its owner cannot pay for its care, it is a tragedy for the animal, its family and also for the veterinary teams. Without a financial solution, the family is sometimes forced to consider euthanising the animal. This unbearable situation leads to a feeling of anger, injustice and incomprehension on the part of the owner, but also on the part of the veterinary teams, who are powerless in the face of these situations which go against their vocation of care. This is how they created Vetericare, which offers veterinarians a solution to finance the heavy care of animals in life-threatening emergency situations whose owners cannot afford the costs. With funds raised through sponsorship, membership and fundraising, Vetericare offers member veterinary facilities an online platform to submit requests for care. Requests are selected based on the type and prognosis of the disease, the owner’s income and the funds available.

Launch of the 3rd call for projects “Pain & Animal Health”

As the first research foundation in the field of pain, the ANALGESIA Institute is launching, for the 3rd consecutive year, the call for STARTER projects “Pain & Animal Health” granting €18,000, thanks to the renewed support of the Domes Pharma Group.

The field of pain requires therapeutic advances. To meet this major challenge, the ANALGESIA Institute has applied itself to reviving innovation in this field by relying on the One Health concept: a single health for humans and animals. By bringing doctors and veterinarians together, this approach proposes a new R&D model that is inspired by the patient, whether it’s human or animal, to finally offer new treatments that will benefit both humans and animals.
A long-standing player in the veterinary pharmaceutical industry in France, the Domes Pharma Group has put the quality of the relationship between humans and animals at the heart of its vision. By partnering with the ANALGESIA Institute, the Group’s objective is to ensure that the knowledge, consideration and treatment of animal pain, (the existence of which has only been truly accepted since the 1980s) can also benefit from the latest research advances.

The Domes Pharma Group’s commitment, to the ANALGESIA Institute, is formalized by the renewal of the “ANALGESIA – Domes Pharma Pain and Animal Health” award, which will be granted on the basis of a call for projects.

This important support allows the ANALGESIA Institute to commit even further to innovation in pain management for the benefit of the veterinary world over the long term.
For this 3rd edition, the ANALGESIA Institute will grant funding of 18,000 euros. This amount is intended to help an academic team wishing to develop a research theme on pain in animal health to acquire or complete preliminary results that will then allow it to apply for competitive calls for projects (national grant, Horizon Europe…).
The call for projects is open to all academic teams (French or not), who conduct research in this field.

A jury composed of experts in pain research and of experts in animal health will evaluate the files submitted by the candidates. At the end of this evaluation, the Scientific Council of the Foundation will decide on the successful application. The award ceremony will take place during a symposium on pain to be held in the end of 2021.

 

Launch of the call of projects: September 27, 2021
Deadline for applications: November 30 2021 at noon
Award ceremony:  1st quarter 2022

How to apply? 

 

Any questions?

Do not hesitate to contact the ANALGESIA Institute at the following email address:
contact@institut-analgesia.org

 

Dômes Pharma announces the opening of a subsidiary in Germany

Four years after the opening of its first foreign subsidiary in the UK, the veterinary pharmaceutical group Dômes Pharma continues its international development with the opening in January 2021, of a German subsidiary based in Berlin under the name TVM Tiergesundheit GmbH.

Germany is the second largest market for animal health in Europe, behind France and ahead of the United Kingdom. By establishing itself in Germany, the Dômes Pharma Group is giving itself the means to directly address more than 50% of the European market. The opening of this new subsidiary is fully in line with the Dômes Pharma Group and its brand TVM’s strategy, to develop its international business through the opening of subsidiaries in the territories identified as priorities while maintaining distribution partnerships in other countries. According to Anne Moulin-Chauder, President of the Dômes Pharma Group, “We are crossing a line and claiming our role as a European player in animal health.”
Although the Group initially considered the acquisition of a stake in an existing company because the German market is known to be difficult for new entrants, it ultimately favoured the creation of its own subsidiary. Meeting with Luc Goossens, who is now the director of the subsidiary sealed this decision because he appeared to be the man of the situation. He is Belgian, a qualified veterinarian, settled in Germany since 1983 and he has led his entire career in the veterinary pharmaceutical industry with roles in research & development, marketing and management. The Group will be able to draw on his experience and network to successfully enter the German veterinary market.

Gradual deployment in 2021

Within 3 months, Luc Goossens plans to recruit a dozen employees, including a sales team, to visit the 12,000 veterinary clinics in Germany. TVM Tiergesundheit GmbH will first introduce two emblematic skincare products from TVM’s ophthalmological range, in which the laboratory is a leader in France. Next will be 2 food supplements to support osteoarthritis problems in dogs and to combat stress, both formulated with the new super-appetizing ‘Tasty tech’ technology developed by the Dômes Pharma Group to facilitate long-term treatment. Finally, the Anti-Tox range, unique in Europe and already leader in France and the United Kingdom, will enter the market under the TVM banner.

The TVM brand leverages the development of the Dômes Pharma Group’s international ambitions

As was the case for England, Dômes Pharma is established in Germany under the name of its brand and subsidiary TVM, the undisputed leader in ophthalmology, neurology and the management of veterinary intoxications in France.  While the market is dominated by multinationals, TVM has been able to carve out a place for itself by offering innovative products that meet the needs of the daily practice of veterinarians and that fill certain therapeutic gaps.

A good omen

On the occasion of the opening of its subsidiary in Germany, the Dômes Pharma group has chosen a particularity of Berlin for its New Year’ s greetings. Indeed, Berlin has a unique feature. This is the only city in the world where the circular tube line, the «Ringbahn», is the shape of a dog’s head. We interpret this as a good omen for the opening of our subsidiary in Berlin!

Launch of the second call for projects “Pain & Animal Health”

As the first research foundation in the field of pain, the ANALGESIA Institute is launching, for the 2nd consecutive year, the call for STARTER projects “Pain & Animal Health” granting €18,000, thanks to the renewed support of the Domes Pharma Group.

The field of pain has remained on the margins of the great medical advances of the last 50 years. To meet this major challenge, the ANALGESIA Institute has applied itself to reviving innovation in this field by relying on the One Health concept: a single health for humans and animals. By bringing doctors and veterinarians together, this approach proposes a new R&D model that is inspired by the patient, whether it’s human or animal, to finally offer new treatments that will benefit both humans and animals.

A long-standing player in the veterinary pharmaceutical industry in France, the Domes Pharma Group has put the quality of the relationship between humans and animals at the heart of its vision. By partnering with the ANALGESIA Institute, the Group’s objective is to ensure that the knowledge, consideration and treatment of animal pain, (the existence of which has only been truly accepted since the 1980s) can also benefit from the latest research advances.

The Domes Pharma Group’s commitment, to the ANALGESIA Institute, is formalized  by the renewal of the “ANALGESIA – Domes Pharma Pain and Animal Health” award, which will be granted on the basis of a call for projects.

This important support allows the ANALGESIA Institute to commit even further to innovation in pain management for the benefit of the veterinary world over the long term. 

For this 2nd edition, the ANALGESIA Institute will grant  funding of 18,000 euros. This amount is intended to help an academic team wishing to develop a research theme on pain in animal health to acquire or complete preliminary results that will then allow it to apply for competitive calls for projects (national grant, H2020…). In 2019, the prize was awarded to a Franco-Brazilian study project that evaluated different physiotherapy methods for the immediate relief of myofascial pain in dogs.

The call for projects is open to all academic teams (French or not), who conduct research in this field.

Calendar

  • Launch of the call of projects: April 20, 2020
  • Deadline for sending applications: June 26, 2020 at noon      
  • Award ceremony: Autumn 2020       

How to apply?

Download the application form on the ANALGESIA Institute websitehttps://www.institut-analgesia.org/appel-a-projets-douleur-sante-animale-2020/

 Any questions?

Do not hesitate to contact the ANALGESIA Institute at the following email address:  contact@institut-analgesia.org

Download Press release

AWARD OF THE PRIZE ” ANALGESIA – PHARMA DOMES: PAIN AND ANIMAL HEALTH “.

On Thursday 16 January, the winners of the 1st call for projects “ANALGESIA – Pharma Domes: pain and animal health” launched in June 2019 were announced. The selected project is a Franco-Brazilian study project that evaluates different physiotherapy methods for the immediate relief of myofascial pain in dogs. On the initiative of Denise Tabacchi Fantoni, from the Department of Veterinary Surgery at the University of São Paulo (Brazil), and Maira Rezende Formenton, doctoral student, the practical work of the study will be carried out by Karine Portier’s team from VetAgro Sup Lyon with dogs suffering from osteoarthritis presented for consultation at the Centre Hospitalier Universitaire Vétérinaire (CHUV).

Karine Portier, present at the evening event organized at Vetagro Sup Lyon, and her two co-laureates who attended the event by video-conference in São Paulo, were presented with a cheque for €18,000 by Anne Chauder, President of the Dômes Pharma Group. By joining forces with the ANALGESIA Institute, the Group’s objective is to ensure that knowledge, awareness and treatment of animal pain can benefit from the latest research advances. The “ANALGESIA – Dômes Pharma: pain and animal health” prize will be awarded every year for 5 years.

The main objective of the MPSAH study (for Myofascial Pain Syndrome dog human patients) winning this first edition is to map trigger points in arthritic dogs using different diagnostic tools that will then be compared. The second objective is to compare the mapping and characteristics of PMS in humans and dogs. The third objective is to use the results of this study to complete a veterinary exercise thesis (DMV) on pain recognition techniques in animals (e-learning).

The prize was awarded by ANALGESIA and DÔMES PHARMA at the end of a Symposium on animal pain during which Professor Alain ESCHALIER, President of the ANALGESIA Institute, Thierry POITTE, veterinarian, member of the jury and founder of the CAPDouleur Network, and Norin CHAI, chief veterinarian of the Jardin des Plantes zoo, spoke.

The Dômes Pharma Group annouces the creation of its Foundation dedicated to Animal Assisted Therapy

To demonstrate that its strapline Linked by Nature is backed up with real actions and to pay tribute to the passion and values of its founders, the Dômes Pharma Group announces the creation of its Corporate Foundation dedicated to Animal Assisted Therapies. Its mission is to support projects that enable the most vulnerable people to share a moment of complicity, relaxation or care with an animal to benefit from the deep and lasting benefits of this relationship. An important step in the Dômes Pharma Group’s CSR approach and social commitment.

The first project upholded by the Dômes Pharma Foundation aims to study the effect of equitherapy on the quality of life of women diagnosed with breast cancer. This random clinical trial has been conducted on 86 women over 4 years by the Equiphoria Institute, the Centre de Cancérologie du Grand Montpellier and the Association Montpellier Institut du Sein (MIS). Breast cancer is the most common type of cancer and the third leading cause of death among women. Rehabilitation management is essential during the period of remission,  especially to limit the risk of recurrence.

Horses are very helpful in the field of healthcare no matter what the problem caused by the disease. On a psychological level, they are able to perceive, respond and learn from the feelings they can sense through minimal sensory stimuli; thus they guide the therapist and the patient on the path to reconstruction. On a physical level, the movement of the horse and the interaction with the patient, allows reinforcement of the functional capabilities.

Pascale, in the photo with the horse “Winner” for the Group’s New Year’s card, is one of the participants of the program. She shared with us her testimony on the benefits of this therapy:

“I had no idea how much work and contact with a horse could transform so profoundly.
Only three sessions were enough to give me  my smile back, my self-confidence and my life. Because with a horse you are not in the mind, you can’t tell him stories and neither can he.
The horse projects us into reality and sends us back an image of ourselves from which we cannot escape because it is an evidence, we are in the feeling.
Thanks to the multidisciplinary team that provides support, tools and encouragement, we emerge transformed from such an experience. For me it’s a rebirth! ” Pascale M.

Witnessing the unique bond between Humans and Animals for over 70 years, the Dômes Pharma Group is proud of this new step in its social commitment. The Foundation will make it possible to ensure that its activities are sustainable and have a real impact on beneficiaries. Three experts in animal mediation and adapted sports have agreed to sit on the Foundation’s board. They are Yasmine Debarge (CANIDEA), Hélène Viruega (EQUIPHORIA) and Sonia Wittreck (Veterinarian of the Disabled Sports Federation). They will assist the Foundation in the choice of projects to be supported by ensuring that they bring benefits to Humans while respecting the well-being of the Animal.

 

The ANALGESIA Institute Foundation commits against pain in animal health with the support of the DÔMES PHARMA Group

As the first research foundation in the field of pain, the ANALGESIA Institute is launching a call for STARTER projects “Pain & Animal Health” in 2019 granting €18,000, thanks to the support of the Domes Pharma Group.

The field of pain has remained on the margins of the great medical advances of the last 50 years. To meet this major challenge, the ANALGESIA Institute has applied itself to reviving innovation in this field by relying on the One Health concept: a single health for humans and animals. By bringing doctors and veterinarians together, this approach proposes a new R&D model that is inspired by the patient, whether it’s human or animal, to finally offer new treatments that will benefit both humans and animals.

A long-standing player in the veterinary pharmaceutical industry in France, the Domes Pharma Group has put the quality of the relationship between humans and animals at the heart of its vision. By partnering with the ANALGESIA Institute, the Group’s objective is to ensure that the knowledge, consideration and treatment of animal pain, (the existence of which has only been truly accepted since the 1980s) can also benefit from the latest research advances.

The Domes Pharma Group’s commitment, to the ANALGESIA Institute, is formalized in concrete terms with the creation of the “ANALGESIA – Domes Pharma Pain and Animal Health” award, which will be granted on the basis of a call for projects for 5 consecutive years.

This important support allows the ANALGESIA Institute to commit even further to innovation in pain management for the benefit of the veterinary world.

For this 1st edition, the ANALGESIA Institute will grant  funding of 18,000 euros. This amount is intended to help an academic team wishing to develop a research theme on pain in animal health to acquire or complete preliminary results that will then allow it to apply for competitive calls for projects (national grant, H2020…).

The call for projects is open to all academic teams who conduct research in this field.

A jury composed of experts in pain research and of experts in animal health will evaluate the files submitted by the candidates. The award ceremony will take place during a symposium on pain to be held in December 2019.

Calendar

Launch of the call of projects                              June 20, 2019
Deadline for sending application                      September 30, 2019         
Announcement of the winning project          mid-November 2019
Award ceremony                                                         December 2019

How to apply?
Download the application form on the ANALGESIA Institute websitehttp://www.institut-analgesia.org/aap-douleur-et-sante-animale/

Any questions?
Do not hesitate to contact the ANALGESIA Institute at the following email address:  contact@institut-analgesia.org

 

About the ANALGESIA Institute

Accredited by the French Ministry of Research since February 2016, The ANALGESIA Institute is the first research foundation dedicated to innovation against pain in France. It draws on more than 20 years of expertise in pain research. The foundation acts by building and coordinating care and research programmes, with one fundamental principle: to put the patient at the heart of each project.

New drugs, new e-health approaches and new technologies (big data, algorithms, machine learning…), a multidimensional innovation with a single objective: to enable patients, whether human or animal, to regain a pain-free life!

 

For more information, www.institut-analgesia.org

Dômes Pharma Group acquires a stake in StemT Laboratory, specialist stem-cell therapy for veterinary applications

The Dômes Pharma group, a long-standing player in animal health, announces an equity investment in StemT, a French start-up specialising in the veterinary use of stem cells.

Founded and chaired since 2015 by Thibault Lataillade, StemT is a French biotechnology laboratory specialising in veterinary cell therapy for horses, dogs and cats. StemT’s mission is to expand the use of veterinary stem cells and to offer innovative and accessible treatments for inflammatory, orthopaedic and immunologicaldiseases. The Laboratory has numerous scientific partnerships with French universities, in particular the ENV-Alfort and VetAgro Sup Veterinary Schools, INSERM and the University of Paris 13.

Like the Dômes Pharma Group, StemT is a family company that carries out all of its R&D and production in France. These common points have convinced Anne Chauder, President of the Group, to invest in this young company: “This decision confirms the Dômes Pharma Group’s desire to be involved in the research of innovative therapies for the fields in which our subsidiary, the TVM Laboratory, has historically been innovative, such as ophthalmology or neurology. Stem cells open up countless therapeutic possibilities and hopes for curing previously incurable diseases. We are proud to support the research of the StemT teams and to be associated with the progress that will be made in the coming years.”

Stem cells: a promising therapy

Stem Cell Therapy, which consists of injecting stem cells into the patient to restore the activity of a tissue or organ, offers tremendous hope for pathologies with an inflammatory and degenerative component. For humans, the use of stem cells is the subject of many trial programs to treat various diseases such as Parkinson’s disease, DNLA, certain types of cancers, etc. Several hundred projects involving this type of therapy are underway around the world.

Animal health also has high hopes for cellular therapies. In the United States, several thousand dogs already benefit from cellular therapies in the treatment of osteoarthritis, a technique that has long been used for horses in the United Kingdom. There are also countless possible applications and StemT deploys therapies in other areas such as cat caudal stomatitis, which degrades the animal’s mouth and can lead to euthanasia or the treatment of chronic inflammatory disease of the dog’s intestine – the equivalent of Crohn’s disease.

 

TVM UK inaugurates new eco and pet-friendly office in Kirtlington

On October 17, TVM UK, the English subsidiary of TVM Lab, inaugurated its new Kirtlington office. What a long way we’ve come in 2 years! Since the acquisition of Forum Animal Health by Dômes Pharma Group and a significant entry into the British veterinary pharmaceutical industry under the name TVM UK in November 2017, this move marks another milestone. The team has chosen to leave Redhill and settle as close as possible to nature, in the rural and peaceful surroundings of Oxford. It is in this new setting that the launch of the Corneal Focus ophthalmic range is being prepared, which will be presented in November at the London Vet Show. 

More than just offices, it is a lifestyle choice made by the TVM UK team. Anne Chauder, President of the Dômes Pharma Group, shared this enthusiasm: “I was immediately seduced by the location chosen by Mark Leddy and his team for TVM UK’s new premises: an authentic place, in the heart of nature, both soothing and inspiring. The layouts they have made in the offices reflect their image: creative, welcoming and eco-responsible. The result is a place that employees and their pets immediately adopted. »  

The Kirtlington Business Centre is an atypical place both in appearance and philosophy. Located on Slate Farm, a former Oxfordshire dairy farm, it has been renovated to preserve its authenticity while taking particular care to preserve the environment; a concern shared by both owners and occupants of the premises. To respect the philosophy of the place and their own convictions, TVM UK employees have decreed a “Plastic Free Zone” office by banning disposable dishes and plastic bottles.

 

 

The offices have been designed with the aim of preserving this proximity to nature and making it a welcoming and inspiring place. The living moss wall and the welcome panel in the reception area (which also offers an area to hang dog toys, leads etc), set the tone: 2 legs or 4 legs, all are members of the team and share the dream of living in the countryside. The possibility of coming to work with your animal was part of the specifications, which some members of the team are now doing.

Eco-Friendly and Pet-friendly, TVM UK’s new offices are in perfect harmony with the slogan and spirit of Dômes Pharma group: “Linked by Nature”.

Arrival of a soft chew range for animal health medicines and food supplements

EUROPHARTECH selected the CPhI 2018 in Madrid to inform customers and partners of the imminent arrival of a ‘soft chew’ range, designed for the production of animal health medicines and food supplements. EUROPHARTECH is aware that compliance with treatment is a critical point for the support of a sick animal and has already acquired solid experience in the development of palatable food supplements and medicines.

With this new investment of nearly 2M€ – which will be fully operational by year-end – EUROPHARTECH intends to develop a real specialty that will be proposed as full service, from formulation to the finished product. Soft Chew samples and applications will be presented at the CPhI Madrid (October ç-11) on stand 3F73.

This galenic form is characterized by a high percentage of palatable agents facilitating mono-dose treatments but also improving the observance of long-term treatments, making it popular with veterinarians and pet owners.

This galenic form is not more prevalent in animal health today due to the difficulty of producing homogeneous dosage forms by extrusion. To avoid this problem, Europhartech opted for specific compression technology that allows for optimum control of the active principle unit mass and therefore the quantity of active principle contained in each unit produced. The palatable rate implemented in this technology can even mask certain active components that our four-legged companions do not appreciate. Diverse formulations can produce both medication (antibiotics, anti-parasitic, neurological…) and food supplements (vitamins, minerals, plant extracts…).